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of other known risk factors (MELD p ¼ 0.0055; MELDNa p ¼ 0.0083). Anticoagulant use was associated with poor
survival at 1 year (73.7% vs. 86.4%; p ¼ 0.0118), and the statistical signiﬁcance of MELD/MELDNa was higher in
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patients receiving oral anticoagulation therapy.Conclusions Assessment of liver dysfunction according to the MELD scoring system provides additional risk information in
ambulatory patients with heart failure. (J Am Coll Cardiol 2013;61:2253–61) ª 2013 by the American College of
Cardiology FoundationVarious scoring models have been useful in assessing risk in
patients with heart failure (HF). Peak oxygen consumption
(VO2) collected during cardiopulmonary exercise testing, the
Heart Failure Survival Score (HFSS), and the Seattle Heart
Failure Model (SHFM) have all been shown to effectively
identify patients at high risk for clinical events and death in
cohorts of clinically stable, ambulatory HF patients (1–3).
However, although the current models used during heart
transplantation (HTx) evaluation incorporate a multitude of
variables, they fail to fully address the impact of liver
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and subsequent cirrhosis in patients with advanced HF, has
long been recognized in clinical settings (4). Moreover,
abnormal results on liver function tests in patients with
HF have been linked to poor outcomes and higher risk of
death (5–7).However, data are limited regarding the usefulness of
composite scoring systems of liver dysfunction in patients with
HF. The established Model for End-Stage Liver Disease
(MELD) scoring system, developed in patients with hepatic
cirrhosis awaiting liver transplantation, may provide infor-
mation in HF patients by measuring the progression of liver
dysfunction based on a patient’s creatinine, total bilirubin, and
international normalized ratio (INR) (8). These 3 laboratory
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2254parameters are noncardiac bio-
markers representing hepatic and
renal dysfunction and their im-
pact on coagulation (9). This
makes the MELD score suitable
for the prognosis of advancedHF,
a state of multiorgan dysfunction
secondary to impaired cardiac
function with known impairment
of hepatic and renal function in
advanced stages of the disease
process. In addition to its estab-
lished role in determining the
urgency for liver transplantation,
the MELD scoring system has
also been shown to be a versatile
tool for outcome prediction in cir-
rhotic patients undergoing cardi-
ac surgery (10,11), patients with
advanced HF undergoing left
ventricular assist device (LVAD)
implantation (12), and patients
undergoing orthotopic HTx
(13).Furthermore, alternative MELD scoring systems may
offer improved prognostic efﬁcacy. This is particularly true
for the MELD-XI score, which excludes INR as a variable
and is thereby a more reliable marker of risk in patients with
elevated INR secondary to anticoagulation (14). Further-
more, another modiﬁcation of MELD, the MELDNa, may
improve prognostic efﬁcacy by incorporating low sodium
levels indicating hyponatremia, a commonly cited marker for
increased mortality in both liver cirrhosis and HF (15,16). In
the current study, we analyzed the strength of these various
MELD scoring systems in predicting the survival of clini-
cally stable outpatients with advanced HF. We assessed
MELD scores during the HTx evaluation process and fol-
lowed up the cohort for a maximum of 3 years after the
initial evaluation. In addition, we compared the prognostic
power of MELD, MELDNa, and MELD-XI in patients
on and off oral anticoagulation regimens.Methods
Study design. We retrospectively evaluated 343 patients
with HF referred for HTx evaluation at Columbia Univer-
sity Medical Center between 2005 and 2009. Patients with
incomplete laboratory datasets (n ¼ 83) were excluded from
the study, leaving 260 patients in the cohort. The clinical
characteristics, medical treatments, laboratory examination
values, and hemodynamic data were collected by using an
electronic chart review of data closest to the evaluation date.
Survival data were collected by using the Social Security
Death Index at the end of the 3-year observation period. If
no death was indicated, the patient was recorded to be alive
at the time of follow-up.The patients in the cohort were categorized according to
oral anticoagulation status, and 3 groups of subjects (all
patients and patients on and off anticoagulation) were
analyzed. The groups were further dichotomized according
to MELD, MELDNa, and MELD-XI scores based on the
optimal cutoff value derived from the receiver-operating
characteristic (ROC) analysis. The laboratory and clinical
characteristics at the time of HTx evaluation were compared
between the groups.
The study was approved by the institutional review board
of Columbia University Medical Center.
Assessment of liver dysfunction by using MELD
scores. The standard MELD score was calculated by using
the following formula (17): 11.2 $ (ln INR) þ 0.378 $ (ln
total bilirubin) þ 0.957 $ (ln creatinine) þ 0.643. We
applied the MELD modiﬁcations adopted by the United
Network for Organ Sharing (18); the lower limit of all
variables was set at 1.0 to prevent negative scores, and the
upper limit for creatinine was set at 4.0 mg/dl. The
MELDNa score was calculated by using the following
formula (15): MELD – serum sodium – 0.025 $ MELD $
(140 – serum sodium) þ 140. The limit for sodium was set
between 125 and 140 mmol/l. The MELD-XI score
formula developed by Heuman et al. (14) was used: 5.11 $
(ln total bilirubin) þ 11.76 $ (ln creatinine) þ 9.44.
Peak VO2, HFSS, and SHFM. Peak VO2 was determined
during the maximal treadmill exercise on a metabolic cart
(Medical Graphics Corporation, Minneapolis, Minnesota).
Three risk groups were deﬁned according to the following
values: peak VO2 >14 ml/min/kg (low risk), peak VO2 10 to
14 ml/min/kg (medium risk), and peak VO2<10 ml/min/kg
(high risk).
The HFSS score was calculated based on the following
equation incorporating 7 variables: ([0.0216 $ resting heart
rate] þ [0.0255 $ mean arterial blood pressure] þ
[0.0464 $ left ventricular ejection fraction] þ [0.0470 $
serum sodium] þ [0.0546 $ peak VO2] þ [0.06083 $
presence (1) or absence (0) of intraventricular conduction
defect (QRS interval 120 ms due to left or right bundle
branch block, nonspeciﬁc intraventricular conduction delay,
or ventricular paced rhythm)] þ [0.693 $ presence (1) or
absence (0) of ischemic cardiomyopathy]), as described
previously (2). The absolute value of HFSS was used in the
analysis. Patients were classiﬁed into 3 risk groups according
to the following guidelines: low risk (8.10), medium risk
(7.20 to 8.10), and high risk (7.19).
The SFHM score was calculated based on 24 variables,
including clinical characteristics (age, gender, New York
Heart Association functional class, weight, left ventricular
ejection fraction, systolic blood pressure, ischemic etiology),
medications (angiotensin-converting enzyme inhibitor,
angiotensin receptor blocker, beta-blocker, statin, aldoste-
rone blocker, loop diuretic–equivalent dose, allopurinol),
device therapy (implantable cardioverter-deﬁbrillator,
cardiac resynchronization therapy), and laboratory data
(lymphocytes percentage and serum sodium, hemoglobin,
Table 1
Baseline Characteristics of All Patients Evaluated for
HTx Eligibility (N ¼ 343)
Age (yrs) 56  14
Male 243 (71)
BMI (kg/m2) 27.7  5.6
Diabetes 75 (22)
Heart rate (beats/min) 75.9  14
Systolic blood pressure (mm Hg) 112  19
Diastolic blood pressure (mm Hg) 72  12
Laboratory examination
WBC (103/ml) 7.7  2.1
Hemoglobin (g/dl) 13.6  2.3
Platelets (103/ml) 226  71
Serum sodium (mEq/l) 138  2.8
BUN (mg/dl) 25.3  15
Creatinine (mg/dl) 1.3  1.4
Total bilirubin (mg/dl) 0.9  0.8
AST (U/l) 25  12
ALT (U/l) 26  15
Albumin (g/dl) 4.4  0.5
INR 1.6  0.8
Total cholesterol (mg/dl) 178  51
BNP (pg/ml) 514  814
Medications
ACE inhibitors 215 (63)
ARBs 55 (16)
Beta-blockers 283 (83)
Statin 140 (41)
Aldosterone antagonist 136 (39)
Oral antidiabetic agents 30 (8.7)
Insulin 24 (7.0)
Prognostic factors
Peak VO2 (ml/min/kg) 12.9  4.81
HFSS 7.45  2.82
SHFM 0.43  0.79
Endpoint events count 63 (26)
Endpoint events due to death 18 (5.6)
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme; ALT ¼ alanine aminotransferase; ARB ¼ angiotensin
receptor blockers; AST ¼ aspartate aminotransferase; BMI ¼ body mass index; BNP ¼ B-type
natriuretic peptide; BUN ¼ blood urea nitrogen; HFSS ¼ Heart Failure Survival Score; HTx ¼ heart
transplantation; INR ¼ international normalized ratio; VO2 ¼ oxygen consumption; SHFM ¼ Seattle
Heart Failure Model; WBC ¼ white blood cells.
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2255uric acid, total cholesterol) (3). Missing continuous variables
were replaced with the mean value for all patients in the
dataset. The SHFM scores were rounded to the nearest
integer between 0 and 4 (scores <0 were considered as 0).
Risk strata were deﬁned as low risk (score 0), medium risk
(score 1), or high risk (score 2).
Statistical analysis. Continuous variables were expressed as
mean  SD and categorical data as percentages. Continuous
variables were compared between the groups by using the
Student unpaired 2-tailed t test, whereas categorical vari-
ables were compared by using the Fisher exact test. A p value
of <0.05 was considered statistically signiﬁcant. The
endpoint events were deﬁned as death, HTx, and ventricular
assist device (VAD) requirement. Pearson’s correlation
analysis was performed between MELD models and right
atrial pressure, pulmonary arterial mean pressure, and cardiac
output.
The prognostic strength of the model and the individual
variables composing the model were compared by calculating
each area under the curve (AUC) from the ROC analysis for
1- and 3-year endpoint events. The ROC curves were
quantitatively compared by using the DeLong test (19), and
the optimal cutoff value for the model was determined by
using the Youden criterion. For uniformity, the average of
MELD, MELDNa, and MELD-XI optimal cutoff values
derived from the 1-year ROC analysis in all patients (N ¼
260) was used to dichotomize the patients according
to MELD score. The average optimal cutoff value (12)
of MELD, MELDNa, and MELD-XI derived from the 1-
year ROC analysis in all patients was set as the standard
number to dichotomize the patients per their MELD score.
The survival rates of 2 MELD score groups were compared
by using Kaplan-Meier methods with a log-rank test. A Cox
proportional hazards analysis was used to assess the associ-
ation between the variables (MELD models, clinical and
laboratory variables) and the occurrence of 3-year endpoint
events in the group of subjects. Variables that achieved
statistical signiﬁcance in the univariate analysis by using all
patients in the cohort were included in the multivariate
analysis. We repeated the multivariate analysis including the
MELD score but excluded any variables composing the
model.
Statistical analyses were performed by using SAS software
JMP version 7.0 (SAS Institute, Inc., Cary, North Carolina)
and MedCalc for Windows version 9.5.0.0 (MedCacl
Software, Mariakerke, Belgium).Results
Baseline characteristics. Clinical characteristics for all
patients evaluated for HTx eligibility (N ¼ 343) are
summarized in Table 1. The group consisted of ambulatory
HF patients; 71% were male with a mean age of 56 years.
Eighteen percent (n ¼ 63) of the study subjects met the
endpoint criteria in which 28% (n ¼ 18) of the events were
due to death. We selected only patients with completelaboratory and clinical data, and our study cohort (n ¼ 260)
was 72% male with a mean age of 54 years (Online Table 1).
The baseline characteristics were further dichotomized
according to MELD, MELDNa, and MELD-XI scores by
using a cutoff value of 12. The comparison between groups
revealed that patients with a higher MELD/MELDNa/
MELD-XI score have poor prognoses. Higher MELD
scores (>12) were associated with lower levels of heart rate,
hemoglobin, albumin, and cholesterol, in addition to higher
levels of blood urea nitrogen and B-type natriuretic peptide.
A similar pattern was observed by using the MELDNa
score, but elevated scores (>12) were also associated with
lower levels of systolic blood pressure and platelets, as well as
a higher level of aspartate aminotransferase. Patients with
high MELD-XI scores were signiﬁcantly older and likely
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2256male with higher INR levels in addition to the baseline
characteristics seen in patients with high MELD scores.
The baseline characteristics for our cohort were also
categorized according to oral anticoagulation therapy and
further dichotomized according to MELD/MELDNa/
MELD-XI scores using the same cutoff value speciﬁed
earlier (Online Table 2A). Of 260 patients, 104 (40%)
received anticoagulation therapy. Patients receiving anti-
coagulation had signiﬁcantly lower serum sodium levels;
otherwise, no signiﬁcant differences in clinical and labora-
tory variables were observed. In patients off anticoagulation
with high MELDNa scores, heart rate, and platelet counts
were no longer signiﬁcantly different, but the white blood
cell count was elevated. The same baseline patterns were
observed in patients not receiving anticoagulation, with high
MELD-XI scores compared with those of all patients with
high MELD-XI scores.
We observed fewer baseline differences between the
dichotomized score groups in patients receiving anti-
coagulation (Online Table 2B). In this group of subjects,
a MELD score >12 was associated with lower levels of
hemoglobin and sodium along with higher levels of blood
urea nitrogen; patients with higher MELDNa scores had
signiﬁcantly higher B-type natriuretic peptide levels. For
MELD-XI, scores >12 were associated with lower body
mass index, hemoglobin, and sodium, along with higher
blood urea nitrogen and INR levels.
Hemodynamic proﬁles for right atrial pressure, pulmonary
arterial mean pressure, and cardiac output were obtained
from 52%, 53%, and 50% of the study subjects, respectively.
The Pearson’s correlation analysis indicated that the MELD
scores positively correlated with right atrial pressure (R ¼
0.26, p ¼ 0.002 for MELD; R ¼ 0.22, p ¼ 0.006 for
MELDNa; and R ¼ 0.20, p ¼ 0.024 for MELD-XI),
pulmonary arterial pressure (R ¼ 0.26, p ¼ 0.002 for
MELD; R ¼ 0.26, p ¼ 0.002 for MELDNa; and R2 ¼
0.17, p ¼ 0.035 for MELD-XI) but not with cardiac output.
Comparison of AUC values of the MELD composite
scoring system and the individual variables of the
composite score. Table 2 summarizes results obtained
from the ROC analysis of all MELD models and their
individual variables for 1-year endpoint events. An
improvement in AUC and p values for 1-year endpoint
events was observed in the MELD scoring models relative to
those of individual variables tested in all patients (N ¼ 260).
The AUCs for creatinine, total bilirubin, INR, and serum
sodium were 0.62 (p ¼ 0.5162), 0.66 (p ¼ 0.0323), 0.70
(p ¼ 0.0111), and 0.64 (p ¼ 0.0158), respectively, whereas
MELD, MELDNa, and MELD-XI had values of 0.71
(p < 0.0001), 0.73 (p < 0.0001), and 0.69 (p ¼ 0.0002).
When the ROC curves were compared by using DeLong’s
method, MELDNa was a stronger predictor for the
endpoint events than creatinine (p ¼ 0.0496) and serum
sodium (p ¼ 0.0421) values alone (Online Table 3). This
improvement with the composite scores was also seen at the
3-year endpoint analysis (Online Table 4).
Figure 1 Kaplan-Meier Survival Curves of All Patients (N ¼ 260) Dichotomized According to MELD Values
Data were dichotomized according to (A) Model for End-Stage Liver Dysfunction (MELD); (B) MELD serum sodium score (MELDNa); and (C) MELD without international
normalized ratio score (MELD-XI) by using the average cutoff value (12) derived from the receiver-operating characteristic analysis for 1-year death/heart transplantation
(HTx)/ventricular assist device requirement. The survivals are represented by the solid red line for patients with low scores (<12) and the solid blue line for patients with
high scores (>12). The p values obtained by the log-rank test were (A) p < 0.0001, (B) p < 0.0001, and (C) p < 0.0001.
Figure 2
Kaplan-Meier Survival Curve of All Patients (N ¼ 260)
Stratiﬁed According to Anticoagulation Use
The survivals are represented by the solid red line for patients not undergoing
anticoagulation treatment (n ¼ 156) and the solid blue line for patients receiving
anticoagulation (n ¼ 104). *Statistically signiﬁcant (log rank test). HTx ¼ heart
transplantation.
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2257When the cohort was categorized according to anti-
coagulation therapy, we observed a notable difference
between the treatment groups in the AUC value obtained
from the 1-year analysis (Table 2). In patients not receiving
anticoagulation, the MELD and MELDNa score became
an impressive discriminator for 1-year death/HTx/VAD
requirement (1-year AUC: 0.81 [p ¼ 0.0001] and 0.84
[p < 0.0001], respectively). Furthermore, the AUC and the
p value improved in the MELD/MELDNa score compared
with creatinine, total bilirubin, INR, and serum sodium
(1-year AUC: 0.66, p ¼ 0.9068; 0.71, p ¼ 0.0154; 0.84,
p ¼ 0.1682; and 0.68, p ¼ 0.0386, respectively). This
improvement was also signiﬁcant between MELDNa and
creatinine (p ¼ 0.0184), as well as serum sodium (p ¼
0.0179) alone (Online Table 3). Similar results were
observed in the 3-year outcome analysis (Online Table 4).
The MELD and MELDNa scores, however, were poor
predictors for the 1-year events in patients on anti-
coagulation (1-year AUC: 0.55 [p ¼ 0.1823] and 0.55
[p ¼ 0.1752], respectively). As expected, the MELD-XI
was the best predictor for 1-year endpoint events among
all models and individual variables of MELD (1-year AUC:
0.61; p ¼ 0.0740) (Table 2). However, the score was not as
strong a predictor compared with the MELD/MELDNa in
patients off anticoagulation, and no signiﬁcant improve-
ments in the AUC of MELD-XI were observed compared
with those of any individual variables (Online Table 3).
Furthermore, in addition to INR, other variables composing
the model were no longer reliable predictors and therefore
contributed to the limitation of MELD models in patients
receiving anticoagulation (1-year AUC: 0.60 [p ¼ 0.1021],
0.59 [p ¼ 0.7316], and 0.59 [p ¼ 0.2893] for creatinine,
total bilirubin, and sodium, respectively).
It was recognized that factors including clinical decision
processes and disease state may inﬂuence HTx and VADevents; therefore, we repeated the 1-year ROC analysis by
using an endpoint event of death only to re-ensure the
validity of the result obtained by using an endpoint of death/
HTx/VAD requirement (Online Table 5). One-year ROC
analysis using only death as an endpoint event conﬁrmed the
results obtained by using the death/HTx/VAD requirement
as endpoint events.
Impact of dichotomized MELD, MELDNa, and
MELD-XI scores. Results of the Kaplan-Meier analyses
comparing survival of patients dichotomized according to
MELD, MELDNa, and MELD-XI are illustrated in
Kim et al. JACC Vol. 61, No. 22, 2013
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2258Figure 1. Patients with a high MELD score (>12) had
signiﬁcantly worse 1- and 3-year survival (1-year survival:
69.3% vs. 90.4%; 3-year survival: 54.6% vs. 77.1%; p <
0.0001). We found a similar survival difference between
patients with high and low scores deﬁned according to
MELDNa (1-year survival: 70.4% vs. 96.6%; 3-year
survival: 58.8% vs. 78.4%; p < 0.0001) and MELD-XI
score (1-year survival: 70.4% vs. 88.1%; 3-year survival:
51.6% vs. 76.5%; p < 0.0001).
From the poor survival seen in patients on anticoagulation
compared to those without anticoagulation (Fig. 1), we
learned that anticoagulation itself may be associated with
increased risks for the endpoint events. In fact, patients
receiving anticoagulation had signiﬁcantly worse survival
than those not treated (1-year survival: 73.7% vs. 86.4%; 3-
year survival: 58.2% vs. 72.4%; p ¼ 0.0118) (Fig. 2). As
a result, the risks associated with anticoagulation use may
inﬂuence the effectiveness of MELD/MELDNa/MELD-
XI score as a predictor for HTx need. When categorized
according to use of anticoagulation, patients off treatment
were more effectively identiﬁed for events according to the
MELD models (Figs. 3A to 3C). One-year and 3-year
survival of patients off anticoagulation with high MELD
scores (>12) were distinctly lower (1-year survival: 59.2% vs.
92.9%; 3-year survival: 48.6% vs. 78.5%; p < 0.0001). This
pattern was also observed in patients with high MELDNaFigure 3 Kaplan-Meier Survival Curves of Patients Off and On Antico
Values given for patients off anticoagulation (n ¼ 156; top) and on anticoagulation (n ¼ 10
(right) scores by using the cutoff value of 12. The survivals are represented by the solid red lin
(>12). The p value obtained by using the log-rank test in patients off anticoagulationwas (A)
rank test in patients on anticoagulation was (D) p ¼ 0.5300, (E) p ¼ 0.3236, and (F) p ¼scores (>12) (1-year survival: 68.3% vs. 97.5%; 3-year
survival: 62.1% vs. 78.2%; p ¼ 0.0004) and high MELD-
XI scores (>12) (1-year survival: 72.8% vs. 94.6%; 3-year
survival: 61.2% vs. 79.1%; p ¼ 0.0006). MELD-XI was
the only model, however, that effectively stratiﬁed patients’
risk when they were treated with oral anticoagulation (1 year:
66.4% vs. 78.4%; 3 years: 39.7% vs. 71.8%; p ¼ 0.0136)
(Figs. 3D to 3F). No signiﬁcant survival difference was
observed in patients with higher MELD and MELDNa
scores in the cohort on anticoagulation, indicating the
impact of INR on these scores (p ¼ 0.5300 and p ¼ 0.3236,
respectively).
Impact of MELD/MELDNa/MELD-XI on survival
prediction. Cox proportional hazards analysis revealed that
an elevation in MELD/MELDNa/MELD-XI score was
associated with an increased risk for clinical events (hazard
ratio [HR]: 1.10 [95% conﬁdence interval (CI): 1.06 to 1.14],
p < 0.0001 for MELD; HR: 1.10 [95% CI: 1.06 to
1.14], p< 0.0001 for MELDNa; HR: 1.13 [95% CI: 1.07 to
1.19], p ¼ 0.0001 for MELD-XI). Body mass index, mean
arterial blood pressure, hemoglobin, blood urea nitrogen,
serum sodium, INR, B-type natriuretic peptide, cholesterol,
and peak VO2 consumption were individually associated
with increased risks for endpoint events (Table 3), but only
mean arterial blood pressure, INR, and peak VO2 were
independent predictors in the multivariate analysis (Onlineagulation
4; bottom) further dichotomized by MELD (left), MELDNa (middle), and MELD-XI
e for patientswith low scores (<12) and the solid blue line for patients with high scores
p<0.0001, (B) p¼0.0004, and (C) p¼0.0006. The p value obtained by using the log-
0.0136. *Statistically signiﬁcant (log rank test). Abbreviations as in Figure 1.
Table 3 Univariate Analysis of Factors Associated With 3-Year Death/HTx/VAD Requirement
Variable
All Patients (N ¼ 260) Patients off Anticoagulation (n ¼ 156) Patients on Anticoagulation (n ¼ 104)
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
MELD 1.10 (1.06–1.14) <0.0001 1.19 (1.10–1.29) <0.0001 1.06 (0.99–1.13) 0.0816
MELDNa 1.10 (1.06–1.14) <0.0001 1.20 (1.11–1.30) <0.0001 1.06 (1.00–1.13) 0.0620
MELD-XI 1.13 (1.07–1.19) <0.0001 1.14 (1.05–1.22) 0.0020 1.13 (1.03–1.23) 0.0098
Age 1.01 (0.99–1.03) 0.4751 1.00 (0.98–1.03) 0.7488 1.01 (0.98–1.04) 0.6499
Male 0.89 (0.51–1.63) 0.6936 0.98 (0.43–2.53) 0.9717 0.76 (0.36–1.74) 0.4926
BMI 0.93 (0.88–0.97) 0.0030 0.94 (0.87–1.00) 0.0688 0.89 (0.81–0.96) 0.0046
Diabetes 1.44 (0.78–2.52) 0.2304 2.26 (0.95–5.02) 0.0634 0.95 (0.38–2.11) 0.9142
Heart rate 0.99 (0.97–1.01) 0.4903 1.00 (0.97–1.02) 0.9042 0.99 (0.97–1.02) 0.5401
Mean arterial BP 0.95 (0.93–0.97) <0.0001 0.95 (0.91–0.98) 0.0006 0.95 (0.92–0.98) 0.0006
Atrial ﬁbrillation 1.49 (0.81–2.68) 0.1942 1.39 (0.40–3.67) 0.5630 0.91 (0.40–2.14) 0.8240
Laboratory examination
WBC 0.94 (0.82–1.08) 0.4203 0.98 (0.80–1.19) 0.8597 0.88 (0.71–1.08) 0.2306
Hemoglobin 0.69 (0.60–0.81) <0.0001 0.59 (0.48–0.74) <0.0001 0.80 (0.63–1.00) 0.0482
Platelets 1.00 (1.00–1.00) 0.8401 1.00 (1.00–1.01) 0.4890 1.00 (0.99–1.01) 0.8764
Serum sodium 0.87 (0.80–0.96) 0.0062 0.85 (0.72–1.02) 0.0758 0.91 (0.82–1.02) 0.1081
BUN 1.03 (1.01–1.04) <0.0001 1.02 (1.00–1.04) 0.0189 1.05 (1.03–1.07) <0.0001
Creatinine 1.09 (0.89–1.22) 0.3506 1.04 (0.73–1.22) 0.7521 1.83 (1.15–2.62) 0.0155
Total bilirubin 1.24 (1.03–1.43) 0.0237 1.25 (0.94–1.53) 0.1113 1.21 (0.92–1.46) 0.1487
AST 1.01 (0.99–1.03) 0.2662 1.02 (0.99–1.06) 0.1202 1.00 (0.97–1.02) 0.9332
ALT 1.00 (0.98–1.02) 0.9180 0.99 (0.96–1.01) 0.3889 1.01 (0.98–1.02) 0.4987
Albumin 0.91 (0.45–1.91) 0.8082 0.53 (0.19–1.55) 0.2443 1.74 (0.62–5.23) 0.3004
INR 1.48 (1.13–1.88) 0.0060 2.13 (0.91–3.97) 0.0766 1.21 (0.80–1.74) 0.3452
Total cholesterol 0.99 (0.98–0.99) <0.0001 0.98 (0.98–0.99) 0.0002 0.99 (0.98–1.00) 0.0150
BNP 1.00 (1.00–1.00) <0.0001 1.00 (1.00–1.00) <0.0001 1.00 (1.00–1.00) 0.0576
Peak VO2 0.84 (0.78–0.90) <0.0001 0.79 (0.70–0.88) <0.0001 0.90 (0.81–0.99) 0.0327
BP ¼ blood pressure; CI ¼ conﬁdence interval; HR ¼ hazard ratio; VAD ¼ ventricular assist device; other abbreviations as in Tables 1 and 2.
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2259Table 5). In the repeated multivariate analysis including the
composite models, the MELD and MELDNa scores were
independent predictors for clinical events (Table 4).
The elevated MELD/MELDNa/MELD-XI scores were
also strongly correlated with clinical events in patients off
anticoagulation (HR: 1.19 [95% CI: 1.10 to 1.29],
p < 0.0001 for MELD; HR: 1.20 [95% CI: 1.11 to 1.30],
p < 0.0001 for MELDNa; and HR: 1.14 [95% CI: 1.05 to
1.22], p ¼ 0.0020 for MELD-XI). Mean arterial blood
pressure, hemoglobin, serum sodium, cholesterol, blood urea
nitrogen, B-type natriuretic peptide, and peak VO2 were
individually associated with increased risk for endpoint
events (Table 3), but only mean arterial blood pressure,
B-type natriuretic peptide, and peak VO2 were independent
predictors (Online Table 6). When the multivariate analysis
included the risk models, all MELD models were inde-
pendent predictors for HTx need in this group of patients
(Table 4).Table 4
Summary of the Multivariate Analysis Including MELD Mode
3-Year Death/HTx/VAD Requirement
Variable
All Patients (N ¼ 260) Patients o
HR (95% CI) p Value HR (95%
MELD 1.07 (1.02–1.13) 0.0055 1.25 (1.09
MELDNa 1.06 (1.02–1.11) 0.0083 1.24 (1.07
MELD-XI 1.05 (0.95–1.16) 0.3154 1.20 (1.02
Abbreviations as in Tables 1, 2, and 3.On the contrary, MELD-XI was the only model that was
individually associated with the endpoint events in patients
receiving anticoagulation, along with body mass index, mean
arterial blood pressure, blood urea nitrogen, and peak VO2.
However, MELD-XI score was no longer a signiﬁcant
factor for events in the multivariate analysis (Table 4), and
only body mass index, blood urea nitrogen, and total
cholesterol remained independent predictors for the
endpoint events (Online Table 6).
Discussion
Liver abnormalities in patients with HF have a strong
impact on prognosis and risk assessment. In this retro-
spective study, we found that MELD, an established scoring
system for liver dysfunction, was used to successfully risk-
stratify ambulatory patients with HF. MELD scores corre-
late with hemodynamic variables indicative of rightls With the Factors Associated With
ff Anticoagulation (n ¼ 156) Patients on Anticoagulation (n ¼ 104)
CI) p Value HR (95% CI) p Value
–1.42) 0.0025 0.99 (0.92–1.07) 0.8739
–1.42) 0.0055 0.98 (0.92–1.05) 0.5975
–1.41) 0.0326 0.98 (0.86–1.11) 0.7895
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2260ventricular dysfunction. The composite models were
improved discriminators for the death/HTx/VAD require-
ment compared with individual variables comprising the
score. Elevated MELD scores were associated with poor
survival and greater risk of clinical events. Notably, these
relationships were more prominent in patients not treated
with oral anticoagulation. For patients treated with anti-
coagulation, MELD-XI provided moderate but limited risk
information on HTx need.
Previous studies have demonstrated that the combination
of risk models performs better as a predictor for clinical
events in HF patients. Additional evaluation using the HFSS
in patients with high-risk peak VO2 (<10 ml/min/kg)
further stratiﬁed subjects at higher risk for HTx need (20).
Furthermore, the combination of HFSS and SHFM has
been shown to be a better predictor of events, particularly in
the medium-risk group (21). In the current study, we found
that the MELD model provides risk information that is
independent of the variables such as peak VO2 used in the
current HTx evaluation models; therefore, MELD is an
excellent tool to complement the existing evaluation
methods. When MELD scores and peak VO2/HFSS/
SHFM were combined, low MELD score (<12) within the
low-risk group conﬁrmed patient clinical stability (<1 year),
whereas high scores (>12) within the medium-risk group
identiﬁed patients with increased risk (Online Figs. 1
and 2). This additional risk information would be partic-
ularly helpful in determining patients at higher risk within
the current medium-risk group based on assessment of peak
VO2/HFSS/SHFM, which is often considered to be the
“gray area.”
Most notably, MELD scores can be used to continuously
evaluate HF patients’ risk over the course of their disease
progression. Contrary to the SHFM and HFSS models,
which can only evaluate relatively stable ambulatory HF
patients, the MELD score has been shown to identify risk in
end-stage HF patients undergoing LVAD implantation
(12) and orthotopic HTx (13) as well. Moreover, compar-
ison of presurgical and postsurgical MELD scores was
shown to reﬂect the reversibility of HF progression of
patients with improved HF after intervention (12,13). Along
with the relative ease of obtaining the score, this feature
would help clinicians to monitor improvement or advance-
ment in the patient’s risk between early, late, and post-
LVAD/HTx stage of HF. Hence, we strongly support the
use of the MELD score as a routine tool to complement the
peak VO2 value during the evaluation of HF patients for
HTx. To our knowledge, this is the ﬁrst study supporting
the use of MELD scores as a tool for HTx evaluation in
a cohort of ambulatory patients with advanced HF.
Of note, MELD-XI was the only MELD score with
signiﬁcant power to predict lower survival in patients
receiving anticoagulation therapy. However, it has limited
prognostic power in patients undergoing anticoagulation
treatment compared with patients not receiving anti-
coagulation therapy. In fact, anticoagulation itself was a riskfactor for poorer outcome in patients with HF (Fig. 2).
Anticoagulation was likely prescribed to patients who were
sicker due to multiple other comorbidities requiring anti-
coagulation; in particular, atrial ﬁbrillation was more
frequently observed in patients taking warfarin (p < 0.0001),
which indicates greater risk for either ischemic stroke or
hemorrhage secondary to anticoagulation (Online Table 2A).
The WASH (Warfarin/Aspirin Study in Heart Failure) and
WARCEF (Warfarin Versus Aspirin in Reduced Cardiac
Ejection Fraction) studies showed no signiﬁcant beneﬁt of
warfarin use inHF patients with sinus rhythm compared with
aspirin use and because of a reduced risk of ischemic stroke
with warfarin, use may have been offset by an increased risk of
hemorrhage secondary to anticoagulation (22,23). The
MELD score, which quantiﬁes the degree of hepatic and
renal dysfunction, is likely limited in addressing risk
contributed by sudden cardiovascular events such as stroke or
hemorrhage. Further analysis revealed that patients’ risk
identiﬁed by using the HFSS score, which includes etiology
of HF, was not signiﬁcantly inﬂuenced by anticoagulation
(Online Fig. 2). Therefore, to address this limitation,
MELD-XI should be used in combination with several other
risk models such as HFSS to evaluate risk in HF patients
treated with anticoagulation.
Our study also supports the incorporation of serum
sodium in the MELD score to provide additional risk
information for ambulatory patients with advanced HF.
Hyponatremia is a common condition in HF patients caused
by activation of the renin-angiotensin system associated with
the disease (24). Decreased cardiac output of HF leads to
a continued release of vasopressin and activation of multiple
neuronal hormones that cause ﬂuid retention despite the
reduction in serum osmolarity; this imbalance is further
exaggerated by the reduction in glomerular ﬁltration rate.
Not only is hyponatremia common, but it is also a marker of
increased risk for poor outcome in HF patients (25,26). In
OPTIME-CHF (Outcomes of a Prospective Trial of
Intravenous Milrinone for Exacerbations of Chronic Heart
Failure), patients with the lowest admission serum sodium
levels had the poorest outcome (27). In the current study, we
found that the incorporation of serum sodium with the
MELDNa resulted in improved prognostic power (Table 2),
and we support the use of MELDNa for patients not treated
with anticoagulation to evaluate their risk.
Study limitations. Due to its retrospective observational
analysis, the study could not establish causal relationships
and is subject to inherent biases. Our database does not
include echocardiographic or invasive data or information on
the degree of HF status. In addition, the components of the
MELD score are subject to laboratory variations. For
example, serum sodium levels are highly variable by time,
and the use of ﬂuid restriction and diuretic agents may
bypass the purpose of the sodium component in the model.
Lastly, due to the ambulatory nature of our cohort, there is
limited information on the medications prescribed by the
primary physicians.
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2261Conclusions
This single-center, retrospective study demonstrated the
prognostic effectiveness of various MELD scoring systems
in a cohort of ambulatory patients with HF. An elevated
MELD/MELDNa score was strongly associated with an
increased risk that is independent of the current HTx
evaluation models; this relationship was strengthened when
patients were not undergoing oral anticoagulant therapy. For
patients receiving anticoagulation therapy, MELD-XI
provided moderate but limited risk information. The use
of the MELD scoring system might complement and
enhance the current HTx evaluation models for ambulatory
patients with advanced HF.
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